Cargando…
Anticoagulation Therapy Considerations in Factor VII Deficiency
Factor VII (FVII) deficiency is the most prevalent rare bleeding disorder in the USA and affects approximately 1 out of every 500,000 people. Warfarin inhibits the synthesis of FVII, in addition to other clotting factors. Warfarin is contraindicated in patients with bleeding tendencies or blood dysc...
Autores principales: | Paulus, Eric, Komperda, Kathy, Park, Gabriel, Fusco, Julie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005634/ https://www.ncbi.nlm.nih.gov/pubmed/27747688 http://dx.doi.org/10.1007/s40800-016-0031-y |
Ejemplares similares
-
Acquired deficiency of coagulation factor VII
por: da Silva, Vanessa Afonso, et al.
Publicado: (2015) -
Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven(®))
por: Bartosh, Nicole S, et al.
Publicado: (2013) -
A Neonate with Acquired Factor VII Deficiency Successfully Managed with Immunomodulatory Therapy
por: Alqarni, Nof Saadi, et al.
Publicado: (2021) -
A case of intracranial hemorrhage in a neonate with congenital factor VII deficiency
por: Lee, Won Seok, et al.
Publicado: (2010) -
Anterior segment dysgenesis in a child with factor VII deficiency
por: Beby, Francis, et al.
Publicado: (2007)